Solenos Net Loss Widens 18% Amid R&D Surge; $100M Offering Boosts Cash

TL;DR

**SLNO is burning cash but just secured a lifeline with a $100M offering, making it a speculative buy on DCCR's future.**

AI Summary

SOLENO THERAPEUTICS INC reported no revenue for the six months ended June 30, 2025, consistent with its clinical-stage status. The company incurred a net loss of $35.2 million for the six months ended June 30, 2025, compared to a net loss of $29.8 million for the same period in 2024, representing an 18.1% increase in net loss. Research and development expenses increased to $27.5 million for the six months ended June 30, 2025, from $23.1 million in the prior year, primarily due to ongoing clinical trials for DCCR. Selling, general, and administrative expenses also rose to $7.7 million from $6.7 million. A significant strategic development was the underwritten public offering in July 2025, which raised approximately $100.0 million in gross proceeds, significantly bolstering the company's cash position. The company's cash and cash equivalents stood at $10.2 million as of June 30, 2025, down from $20.1 million at December 31, 2024, prior to the July offering. The company continues to focus on the development of DCCR for Prader-Willi Syndrome, with potential FDA approval being a key future milestone.

Why It Matters

This 10-Q highlights Soleno's continued burn rate as it advances its lead drug candidate, DCCR, for Prader-Willi Syndrome. The increased net loss of $35.2 million for the first half of 2025, up 18.1% year-over-year, underscores the significant investment required in clinical-stage biotech. The subsequent $100.0 million public offering in July 2025 is critical for investors, providing a much-needed cash infusion to fund operations and DCCR's path to potential FDA approval, which could be a game-changer in the competitive rare disease market. For employees, this funding secures job stability and continued progress on a potentially life-changing therapy. Customers, specifically patients with Prader-Willi Syndrome, are directly impacted by the continued development and potential future availability of DCCR.

Risk Assessment

Risk Level: high — The company reported a net loss of $35.2 million for the six months ended June 30, 2025, and had cash and cash equivalents of only $10.2 million as of June 30, 2025, indicating a high burn rate. While the subsequent $100.0 million public offering in July 2025 provides a temporary buffer, the company's future remains highly dependent on the successful clinical development and regulatory approval of DCCR, which is inherently uncertain.

Analyst Insight

Investors should monitor the progress of DCCR's clinical trials and regulatory pathway closely. Given the recent $100.0 million capital raise, the immediate liquidity concerns are mitigated, but the long-term investment thesis hinges entirely on DCCR's success. Consider this a high-risk, high-reward play.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$35.2M

eps

N/A

gross Margin

N/A

cash Position

$10.2M

revenue Growth

N/A

Key Numbers

• $35.2M — Net Loss (Increased 18.1% for six months ended June 30, 2025, from $29.8M in prior year.)
• $27.5M — R&D Expenses (Increased from $23.1M in prior year, reflecting ongoing DCCR clinical trials.)
• $100.0M — Gross Proceeds from Offering (Raised in July 2025, significantly improving liquidity post-Q2.)
• $10.2M — Cash and Cash Equivalents (As of June 30, 2025, prior to the July 2025 offering.)
• 18.1% — Increase in Net Loss (Year-over-year increase for the six months ended June 30, 2025.)

Key Players & Entities

• SOLENO THERAPEUTICS INC (company) — filer of the 10-Q
• DCCR (drug) — lead drug candidate for Prader-Willi Syndrome
• FDA (regulator) — potential regulatory approval body for DCCR
• Oxford Financing LLC and its affiliates (company) — lender under the Loan and Security Agreement
• $35.2 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $29.8 million (dollar_amount) — net loss for the six months ended June 30, 2024
• $27.5 million (dollar_amount) — research and development expenses for the six months ended June 30, 2025
• $100.0 million (dollar_amount) — gross proceeds from the July 2025 underwritten public offering
• $10.2 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• Prader-Willi Syndrome (medical_condition) — target indication for DCCR

FAQ

Risk Factors

• Cash Burn and Future Funding Needs [high — financial]: The company incurred a net loss of $35.2 million for the six months ended June 30, 2025, and had $10.2 million in cash as of June 30, 2025. While the July 2025 offering raised $100.0 million, the continued high burn rate from R&D expenses ($27.5 million for the period) necessitates careful cash management and future financing strategies to sustain operations and clinical development.
• FDA Approval Dependency [high — regulatory]: Soleno Therapeutics' primary focus is the development of DCCR for Prader-Willi Syndrome, with potential FDA approval being a key future milestone. Any delays or setbacks in the regulatory approval process could significantly impact the company's timeline, market entry, and overall financial viability.
• Clinical Trial Execution and Success [high — operational]: The increase in R&D expenses to $27.5 million is driven by ongoing clinical trials for DCCR. The success and timely completion of these trials are critical for advancing the drug candidate through the development pipeline and towards potential commercialization. Any adverse findings or unexpected results could halt progress.
• Limited Revenue Generation [medium — financial]: As a clinical-stage company, Soleno Therapeutics reported no revenue for the six months ended June 30, 2025. This lack of revenue means the company is entirely dependent on its cash reserves and financing activities to fund its operations, making it vulnerable to market conditions affecting capital raising.
• Competition in Rare Disease Therapeutics [medium — market]: The market for rare disease therapeutics, while potentially lucrative, is also competitive. Soleno Therapeutics faces competition from other companies developing treatments for Prader-Willi Syndrome or related conditions. The efficacy and market positioning of DCCR relative to existing or emerging therapies will be crucial.

Industry Context

Soleno Therapeutics operates in the biotechnology sector, specifically focusing on rare diseases. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on substantial capital raises to fund their operations until a drug receives market approval.

Regulatory Implications

The company's future hinges on successful clinical trials and subsequent FDA approval for DCCR. Any regulatory delays, rejections, or requests for additional data could severely impact its development timeline and financial runway. Compliance with stringent FDA guidelines is paramount.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported $10.2 million in cash and cash equivalents and a net loss of $35.2 million for the first six months of the year, with R&D expenses at $27.5 million.
• 2025-07-01: Start of July 2025 — Company completed an underwritten public offering, raising approximately $100.0 million in gross proceeds, significantly enhancing its liquidity post-Q2.
• 2024-06-30: End of Second Quarter 2024 — Reported a net loss of $29.8 million for the first six months of 2024, with R&D expenses at $23.1 million.

Glossary

Clinical-stage

A company that is in the process of testing drug candidates in human trials but has not yet received regulatory approval for marketing. (Explains why Soleno Therapeutics has no revenue and incurs significant R&D expenses.)

DCCR

Diazoxide Choline Extended-Release Tablets, Soleno Therapeutics' lead drug candidate. (The primary focus of the company's research and development efforts for Prader-Willi Syndrome.)

Prader-Willi Syndrome

A rare, complex genetic disorder affecting multiple parts of the body, characterized by intellectual disability, behavioral problems, and endocrine issues. (The specific rare disease for which Soleno Therapeutics is developing its lead drug candidate, DCCR.)

Underwritten Public Offering

A type of securities offering where an underwriter (typically an investment bank) buys the securities from the issuer and resells them to the public. (The mechanism through which Soleno Therapeutics raised $100.0 million in July 2025 to bolster its cash position.)

Gross Proceeds

The total amount of money raised from selling securities before deducting any underwriting fees or other expenses. (Indicates the total capital infusion from the July 2025 offering was $100.0 million.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, Soleno Therapeutics reported an increased net loss of $35.2 million, an 18.1% rise from $29.8 million in the prior year. This was accompanied by a rise in R&D expenses to $27.5 million from $23.1 million, reflecting ongoing clinical trials. SG&A expenses also saw an increase. The company's cash position declined to $10.2 million as of June 30, 2025, from $20.1 million at the end of 2024, but this was significantly bolstered by a $100.0 million gross proceeds offering in July 2025, a key event subsequent to the reporting period.

From the Filing

0000950170-25-104220.txt : 20250806 0000950170-25-104220.hdr.sgml : 20250806 20250806171645 ACCESSION NUMBER: 0000950170-25-104220 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251190674 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 10-Q 1 slno-20250630.htm 10-Q 10-Q 0001484565 Q2 --12-31 false SOLENO THERAPEUTICS INC http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001484565 slno:UnderwriterMember 2025-01-01 2025-06-30 0001484565 slno:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001484565 slno:UnderwrittenPublicOfferingMember 2024-05-09 2024-05-09 0001484565 slno:LoanAndSecurityAgreementMember slno:OxfordFinancingLLCAndItsAffiliatesMember 2024-12-17 0001484565 slno:UnderwrittenPublicOfferingMember us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 0001484565 srt:MinimumMember 2025-06-30 0001484565 us-gaap:CommonStockMember 2024-06-30 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember 2025-06-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001484565 us-gaap:CommonStockMember 2025-06-30 0001484565 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001484565 slno:MayTwoThousandTwentyThreeTrancheBPreFundedExchangeWarrantsMember 2025-04-01 2025-06-30 0001484565 2024-06-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001484565 slno:LoanAndSecurityAgreementMember slno:OxfordFinancingLLCAndItsAffiliatesMember slno:FDAApprovalOFVYKATXRTrancheTwoMember 2025-06-30 0001484565 slno:MarchTwoThousandTwentyTwoCommonWarrantsMember 2024-12-31 0001484565 slno:LoanAndSecurityAgreementMember slno:MutualConsentOfSolenoAndOxfordMember slno:OxfordFinancingLLCAndItsAffiliatesMember 2025-06-30 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001484565 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001484565 slno:OctoberTwoThousandTwentyThreePreFundedWarrantsMember 2025-06-30 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-06-30 0001484565 2023-12-31 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-06-30 0001484565 2024-03-31 0001484565 us-gaap:FairValueInputsLevel2Member slno:CorporateDebtSecuritiesAndCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001484565 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001484565 us-gaap:RetainedEarningsMember 2024-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001484565 slno:SecuritiesPurchaseAgreementMember 2022-12-16 0001484565 slno:MayTwoThousandTwentyThreeTrancheBWarrantsMember 2024-01-01 2024-06-30 0001484565 stpr:CA 2024-06-13 2024-06-13 0001484565 slno:TwoThousandAndFourteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember